Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma
Overview
Pharmacology
Authors
Affiliations
We have previously demonstrated that a low dose of cyclophosphamide (Cy) combined with gene therapy of interleukin-12 (AdIL-12) has a synergistic, although limited, antitumoral effect in mice with colorectal carcinoma. The main mechanism involved in the efficacy of Cy+AdIL-12 was the induction of a specific immune response mediated by cytotoxic T lymphocytes. Our current aims were to evaluate the effects of 4-methylumbelliferone (4Mu), a selective inhibitor of hyaluronan (HA) synthesis, on tumor microenvironment (TME) and to investigate how 4Mu affects the therapeutic efficacy of Cy+AdIL-12. The results showed that 4Mu significantly reduced the amount of tumoral HA leading to a significant decrease in tumor interstitial pressure (TIP). As a consequence, tumor perfusion was improved allowing an increased adenoviral transgene expression. In addition, treatment with 4Mu boosted the number of cytotoxic T lymphocytes that reach the tumor after adoptive transfer resulting in a potent inhibition of tumor growth. Importantly, we observed complete tumor regression in 75% of mice when 4Mu was administrated in combination with Cy+AdIL-12. The triple combination 4Mu+Cy+AdIL-12 also induced a shift toward antiangiogenic factors production in tumor milieu. Our results showed that TME remodeling is an interesting strategy to increase the efficacy of anticancer immunotherapies based on gene and/or cell therapy.
Vitale D, Parnigoni A, Viola M, Karousou E, Sevic I, Moretto P Int J Mol Sci. 2024; 25(14).
PMID: 39062846 PMC: 11276752. DOI: 10.3390/ijms25147607.
Hyaluronic acid metabolism and chemotherapy resistance: recent advances and therapeutic potential.
Liu Z, Hou P, Fang J, Shao C, Shi Y, Melino G Mol Oncol. 2023; 18(9):2087-2106.
PMID: 37953485 PMC: 11467803. DOI: 10.1002/1878-0261.13551.
Small molecule inhibitors of mammalian glycosylation.
Almahayni K, Spiekermann M, Fiore A, Yu G, Pedram K, Mockl L Matrix Biol Plus. 2022; 16:100108.
PMID: 36467541 PMC: 9713294. DOI: 10.1016/j.mbplus.2022.100108.
Cao B, Liu M, Wang L, Zhu K, Cai M, Chen X Nat Commun. 2022; 13(1):6203.
PMID: 36261437 PMC: 9581911. DOI: 10.1038/s41467-022-33968-5.
Vitale D, Icardi A, Rosales P, Spinelli F, Sevic I, Alaniz L Front Oncol. 2021; 11:710061.
PMID: 34676159 PMC: 8524446. DOI: 10.3389/fonc.2021.710061.